Vaxcyte Trial Results Suggest it Could Compete With Pfizer: Is it Worth Buying This Stock Today?
Earlier this week Vaxcyte (PCVX) shared an update on its VAX-31 trial results, which are quite promising. The stock popped nearly 50% on the news, sending shares to an all-time high of $115/share. VAX-31 is the company’s pneumococcal conjugate vaccine. This disease can contribute to more serious illnesses such as pneumonia, meningitis, and various [...]
